Babak Tofighi, MD
NYU Langone Health - Assistant Professor, Department of Population Health
NYU Langone Health - Assistant Professor, Department of Medicine
Research Interests
mHealth, Illicit drug & alcohol use disorders
Principal Investigator, Development of a Text Messaging Tool to Support Buprenorphine Treatment in Primary Care. Active


Shulman M, Choo TH, Scodes J, Pavlicova M, Wai J, Haenlein P, Tofighi B, Campbell ANC, Lee JD, Rotrosen J, Nunes EV (2021).
Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure
Journal of Substance Abuse Treatment, 124, 108292. doi: 10.1016/j.jsat.2021.108292. PMCID: PMC8004552.

El-Shahawy O, Schatz D, Sherman S, Shelley D, Lee JD, Tofighi B (2021).
E-cigarette use and beliefs among adult smokers with substance use disorders
Addictive Behaviors Reports, 13, 100329. doi: 10.1016/j.abrep.2020.100329. PMCID: PMC7772361.

Borda JP, Friedman HL, Castano GA, Rodriguez HA, Munoz CF, Tofighi B (2021).
Barriers to HIV and hepatitis C care for people who inject drugs in Colombia
AIDS Care [Epub 2021 Feb 22]. doi: 10.1080/09540121.2021.1889952.

Tofighi B, McNeely J, Walzer D, Fansiwala K, Demner A, Chaudhury CS, Subudhi I, Schatz D, Reed T, Krawczyk N (2021).
A telemedicine buprenorphine clinic to serve New York City: Initial evaluation of the NYC public hospital system’s initiative to expand treatment access during the COVID-19 pandemic
Journal of Addiction Medicine [Epub 2021 Feb 5]. doi: 10.1097/ADM.0000000000000809.

Tofighi B, El Shahawy O, Segoshi A, Moreno KP, Badiei B, Sarker A, Krawczyk N (2021).
Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter
Journal of Addictive Diseases, 39 (1), 37-45. doi: 10.1080/10550887.2020.1811456.